The Precision Peptide Company Applauds FDA Advisory Committee Vote on Expanded Pathway for BPC-157 and KPV On July 23, 2026, the FDA's Pharmacy Compounding Advisory Committee voted 8-6 (one abstention) to recommend BPC-157 for inclusion on the Section 503A Bulks List
For the modified crosswalk approach, we adjusted (or scaled) the MP RVU for the new/revised code to reflect the difference in work RVU between the source code and the new/revised work RVU (or, if greater, the difference in the clinical labor portion of the fully implemented PE RVU) for the new code
That is why BPC-157 is considered an investigational research peptide by scientific organisations
Well, this sounds just like something that is really exciting, something that Im going to be able to offer to not personally offer, but say, hey, theres something out there that you might need to consult with your physician, consult with Dr